| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10917932 | Radiotherapy and Oncology | 2015 | 7 Pages |
Abstract
Our data show inefficiency of Cetuximab and AIIB2 on top of radiochemotherapy. The functions of KRAS and BRAF in therapy resistance remain unanswered and warrant further preclinical molecular-driven investigations. One promising approach might be β1 integrin targeting for reducing metastatic CRC cell spread.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Mandy Poschau, Ellen Dickreuter, Jenny Singh-Müller, Katja Zscheppang, Iris Eke, Torsten Liersch, Nils Cordes,